The observational study that enrolled 2847 adult patients with severe asthma receiving maintenance systemic corticosteroids, biologics, or uncontrolled on high-dosage inhaled corticosteroids and additional controllers.
Your search for severe asthma returned 397 results
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
The CLEAR study compared clinical outcomes and health resource usage in patients with severe asthma who continued, switched, or stopped their biologic treatment.
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.
Trial enrolled children from disadvantaged urban neighborhoods who have exacerbation-prone eosinophilic asthma
Oral corticosteroid dosage reduction sustained in open-label extension study of dupilumab
An analysis of phase 3 NAVIGATOR trial data assessed the effect of tezepelumab on the percentage of asthma symptomatic days in adults and adolescents.
Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin, an epithelial cytokine involved in the initiation and persistence of airway inflammation.
Tezspire is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
- Loading...
